Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank

       Janssen Research & Development Announces Establishment of Global
          Cross-Pharmaceutical Clinical Trial Investigator Databank

Lilly and Merck are First to Join Janssen in this Pre-Competitive Initiative
to Increase Efficiencies in Clinical Trials

PR Newswire

RARITAN, N.J., Nov. 15, 2012

RARITAN, N.J., Nov. 15, 2012 /PRNewswire/ -- Janssen Research & Development,
LLC (Janssen R&D) today announced the establishment of a global
cross-pharmaceutical Investigator Databank designed to improve efficiencies of
industry-sponsored clinical trials.Merck and Eli Lilly and Company are the
first two companies to join Janssen in this effort.

(Logo: http://photos.prnewswire.com/prnh/20120117/LA36598LOGO)

The new Investigator Databank, established as part of this novel industry
collaboration, will serve as a one-stop repository where key information about
clinical trial sites, such as infrastructure and Good Clinical Practice (GCP)
training records, is housed. This will allow participating pharmaceutical
companies to reducetime-consuming and sometimes redundant administrative work
involved in identifying appropriate clinical trial sites. 

At the outset of every clinical trial, pharmaceutical companies initiate
clinical trial site selection, prequalification and GCP training, which can be
paperwork-heavy and time-consuming for trial sponsors and investigators
alike.By housing critical information about investigators and trial sites in
one place, the databank will reduce time, cost and duplicative efforts, making
it easier for companies to identify appropriate trial sites and investigators
for future clinical trials. Investigator sites that have opted-in to data
sharing will have their relevant information accessible to pharmaceutical
companies participating in the collaboration.This databank will not include
any patient data.

"The current clinical trial environment is inefficient, costly and
unsustainable. TheInvestigator Databank can help expedite the process to
achieve our most important goal – to deliver high-quality, effective novel
medicines to the patients whoare waiting for them," said Andreas Koester, MD,
PhD, Head, Clinical Trial Innovation/External Alliances, Janssen Research &
Development."We are enthusiastic about working with other industry leaders to
collectively apply our expertise, capabilities and shared passion for
advancing science and improving lives."

Earlier this year, Janssen joined nine other companies to launch TransCelerate
BioPharma Inc. ("TransCelerate"), the largest initiative of its kind, which
aims to identify and overcome common drug development challenges in order to
improve the quality of clinical studies and to bring new medicines to patients
faster.The initiative identified the centralization of site prequalification
and training as one of five key projects, and the Janssen-led Investigator
Databank project will serve as a foundation for the TransCelerate initiative.

"Industry collaboration, including pre-competitive data sharing, is critical
to ensuring continued progress to improve industry-wide clinical trial
practices," said newly appointed CEO of TransCelerate BioPharma, Garry Neil,
MD, Partner at Apple Tree Partners and formerly Corporate Vice President,
Science & Technology, Johnson & Johnson. "This work is aligned with
TransCelerate's initial focus on clinical study execution and we encourage
participation from our founding TransCelerate companies to solve industry-wide
challenges in a collaborative environment."

Member companies of TransCelerate who wish to join the Investigator Databank
will automatically qualify for participation. It is anticipated that the
Investigator Databank will be operational by the end of the year and
incorporated into one of the priority projects within TransCelerate by
mid-2013.

The Investigator Databank will be hosted by DrugDev.org, an independent, third
party with expertise in clinical trial information technology and investigator
community management.

Janssen Research & Development, LLC
Janssen Research & Development, LLC (Janssen), is one of the Janssen
Pharmaceutical Companies. Janssen is headquartered in Raritan, N.J. and has
facilities in Europe, the United States and Asia. Janssen is leveraging drug
discovery and drug development in a variety of therapeutic areas, including
Neuroscience, Oncology, Immunology, Infectious Diseases, and Cardiovascular
and Metabolism to address unmet medical needs worldwide.

Janssen Healthcare Innovation and Clinical Trial Innovation
Janssen Healthcare Innovation (JHI) is an entrepreneurial team within Janssen
Research & Development. Through collaborations, JHI is developing products and
services to deliver high-quality, cost-effective healthcare. JHI's Clinical
Trial Innovation team is focused on identifying and testing novel approaches,
processes, technologies, and best practices that have the potential to reduce
trial set up and execution cycle times, and reduce cost.For more information,
go to: www.janssenhealthcareinnovation.com.

Forward Looking Statement
(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995.The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Janssen Research &
Development, LLC and/or Johnson & Johnson.Risks and uncertainties include,
but are not limited to, general industry conditions and competition; economic
factors, such as interest rate and currency exchange rate fluctuations;
technological advances, new products and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approvals; challenges to patents; changes in behavior and spending patterns or
financial distress of purchasers of health care products and services; changes
to governmental laws and regulations and domestic and foreign health care
reforms; trends toward health care cost containment; and increased scrutiny of
the health care industry by government agencies. A further list and
description of these risks, uncertainties and other factors can be found in
Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal
year ended January 1, 2012.Copies of this Form 10-K, as well as subsequent
filings, are available online at www.sec.gov, www.jnj.com or on request from
Johnson & Johnson.Neither Janssen Research & Development, LLC nor Johnson &
Johnson undertake to update any forward-looking statements as a result of new
information or future events or developments.)

SOURCE Janssen Research & Development, LLC

Website: http://www.janssenhealthcareinnovation.com
Contact: Meghan Marschall, Janssen Global Services, +1-201-323-0578,
MMarscha@its.jnj.com, or Seema Kumar, Janssen Global Services,
+1-908-405-1144, SKumar10@its.jnj.com